<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

SU-DHL-4

Description

SU-DHL-4 (Lymphoma CDX Model) 

The SU-DHL-4 line was derived from a diffuse large B-cell lymphoma (DLBCL). It represents one of the most common non-Hodgkin’s lymphoma subtypes. SU-DHL-4 has been widely applied in hematology drug discovery. Its reproducibility makes it valuable for lymphoma translational research. 

Key Features: 

  • Derived from diffuse large B-cell lymphoma. 
  • Represents aggressive B-cell lymphoma. 
  • Suspension growth in culture. 
  • Tumorigenic in xenografts. 

Applications: 
SU-DHL-4 supports development of novel therapies for DLBCL. Researchers use it to study B-cell signaling pathways and therapeutic resistance. It is applied in biomarker discovery and targeted therapy testing. Its reproducibility ensures reliability in preclinical pipelines.

Details
Tumor Type
Lymphoma
Tumor Subtype
DLBCL (GCB)
Organism
Human
Mouse Sex
Female
Mouse Strain
CB-17/SCID
Mutated Genes
EZH2
Mutation: p.Y646S
Effect: Missense Variant
Impact: Likely Pathogenic
TP53
Mutation: p.R273C
Effect: Missense Variant
Impact: Uncertain Significance & Not Provided & Likely Pathogenic & Pathogenic & Pathogenic / Likely Pathogenic
Lumin Data
Proteomics RNASeq WES
Expression Data
Growth Curve
View on Lumin